Mindray(SZ:300760) KAIYUAN SECURITIES·2025-05-22 14:23Investment Rating - The investment rating for the company is "Buy" (maintained) [1][4]. Core Views - The domestic market is poised for recovery, and overseas business is performing strongly. The company is expected to benefit from the gradual recovery of procurement in 2025, leading to a turning point in domestic operations [4][5]. - The company has implemented an active dividend policy, with dividend payouts of 679 million and 1.71 billion for 2024 and 2025 respectively, reflecting a payout ratio of 6% and 65% [5]. - Revenue for 2024 is projected at 36.726 billion (up 5.14%), with net profit attributable to the parent company at 11.668 billion (up 0.74%). For Q1 2025, revenue is expected to be 8.237 billion (down 12.12%), with net profit at 2.629 billion (down 16.81%) [5]. - The company is adjusting its profit forecasts for 2025-2027, expecting net profits of 12.913 billion, 14.869 billion, and 17.143 billion respectively, with corresponding EPS of 10.65, 12.26, and 14.14 [5][7]. - The company is transitioning towards a digital and intelligent ecosystem solution provider, integrating technology to address clinical pain points, with a significant increase in revenue contribution from high-end strategic customers [6]. Financial Summary - The company achieved a revenue of 34.932 billion in 2023, with a projected increase to 40.432 billion in 2025, reflecting a year-on-year growth of 10.1% [7]. - The gross margin is expected to remain stable around 63.7% in 2025, while the net margin is projected at 31.9% [7]. - Return on equity (ROE) is forecasted to decline from 34.7% in 2023 to 24.1% in 2025, indicating a potential decrease in profitability [7]. - The company’s P/E ratio is expected to decrease from 23.0 in 2023 to 20.6 in 2025, suggesting a more attractive valuation over time [7].